{"id":390288,"date":"2019-12-31T00:00:00","date_gmt":"2019-12-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0004-2019-biopharma-gastric-cancer-china-in-depth-china-2019\/"},"modified":"2026-03-31T10:45:48","modified_gmt":"2026-03-31T10:45:48","slug":"concon0004-2019-biopharma-gastric-cancer-china-in-depth-china-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0004-2019-biopharma-gastric-cancer-china-in-depth-china-2019\/","title":{"rendered":"Gastric Cancer | China In-Depth | China | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents are approved to treat this indication: Roche\u2019s Herceptin and Jiangsu Hengrui Medicine\u2019s AiTan. Herceptin is the first-line standard of care for HER2-positive patients and AiTan is approved for third-line patients, irrespective of HER2 status. Several novel targeted therapies\u2014including angiogenesis inhibitors (Eli Lilly\u2019s Cyramza and Chi-Med\u2019s Elunate); a claudin inhibitor (Ganymed\u2019s zolbetuximab), and combination regimens of PD-1\/PD-L1 inhibitors (Bristol-Myers Squibb\u2019s Opdivo, Merck &#038; Co.\u2019s Keytruda, Innovent Biologics\u2019 Tyvyt, and Suzhou Jiangsu Hengrui Medicine\u2019s camrelizumab);\u2014and biosimilars of Herceptin are in late-stage development. The launch and uptake of these novel therapies will lead to significant growth of the gastric cancer therapy market over the 2018-2028 forecast period. However, the need for additional, effective targeted therapies will remain high, representing a lucrative commercial opportunity for drug developers.<\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable gastric cancer population, and how will the drug-treatment rate change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s gastric cancer market and why? What are interviewed experts\u2019 insights on current treatment options? Which clinical needs remain unfulfilled?<\/li>\n<li>What are the key market access considerations for key therapies in the gastric cancer pipeline? What sales \/ uptake could they secure in and what are interviewed experts\u2019 opinions of key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in China\u2019s gastric cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>China In-Depth<\/em>: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>September 2019<\/p>\n<p><strong>Geography<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research<\/strong><\/p>\n<p>Qualitative and quantitative insights from five thought-leading medical oncologists in China, supported by survey data collected for this and other\u00a0DRG\u00a0research.<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed prevalence of gastric cancer by\u00a0<em>HER2<\/em>\u00a0biomarker status and by disease stage. Clinically and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast<\/strong><\/p>\n<p>Ten-year, annualized, drug-level sales and patient shares of key gastric cancer therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>Emerging therapies<\/strong><\/p>\n<p>Phase III\/PR: 10 drugs; Phase II: >10 drugs; coverage of select early-phase products.<\/p>\n","protected":false},"template":"","class_list":["post-390288","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastric-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390288\/revisions"}],"predecessor-version":[{"id":576547,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390288\/revisions\/576547"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}